Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and Toxicity-Reference-Cited by-同舟云学术

Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and Toxicity

Published:2003-01 Issue:1 Volume:169 Page:90-95
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

BÖHLE A.¹,JOCHAM D.¹,BOCK P.R.¹

Affiliation:

1. From the Department of Urology, Medical University of Lübeck, Lübeck, Germany, and IFAG Basel AG, Institute for Medical Research and Biostatistics, Basel, Switzerland

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference26 articles.

1. A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer;Pawinski;J Urol,1996

2. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS);Smith;J Urol,1999

3. Guidelines on bladder cancer;Oosterlinck;Eur Urol,2002

4. Intravesical prophylaxis in bladder cancer: a meta-analysis;Lamm;J Urol,2000

5. Cochrane reviewers handbook;Clarke,2002

Cited by 511 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Experience of organizing BCG therapy for localized bladder cancer in outpatient cancer care centers;Consilium Medicum;2024-08-30

2. Neue Therapieansätze beim nicht-muskelinvasiven Urothelkarzinom der Harnblase – Ist der Organerhalt auch nach BCG (Bacillus Calmette-Guérin) möglich?;Die Urologie;2024-08-23

3. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update;European Urology;2024-08

4. The impact of purified protein derivative prior to intravesical bacillus Calmette-Guérin for the treatment of patients with non-muscle invasive bladder cancer;Minerva Urology and Nephrology;2024-07

5. Mitomycin C vs. Bacillus Calmette–Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients—A comparative analysis from a single center;Urologic Oncology: Seminars and Original Investigations;2024-07